Relationship between left ventricular mass index and 24-h urinary free cortisol and cortisone in essential arterial hypertension

Journal of Hypertension

Volumn 17, Issue 11, 1999, Pages 1583-1588

  Duprez, Daniel ^a   De Buyzere, Marc ^a   Paelinck, Marijke ^a   Rubens, Robert ^a   Dhooge, Willem ^a   Clement, Denis L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

24 h urinary free cortisol; Ambulatory blood pressure; Arterial hypertension; Left ventricular hypertrophy; Left ventricular mass index

Indexed keywords

CORTISONE; HYDROCORTISONE;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SEPTUM; HUMAN; HYDROCORTISONE URINE LEVEL; MALE; PRIORITY JOURNAL;

EID: 0032737909     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917110-00012     Document Type: Article

References (29)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 320:1561-1566.
2. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25:879-884.
3. Sullivan JM, van der Zwaag R, El-Zeky F, Ramaanathan KB, Mirvis DM. LV hypertrophy: effect on survival. J Am Coll Cardiol 1993; 22:508-513.
4. Drayer JIM, Weber MA, De Young DL. Blood pressure as a determinant of cardiac left ventricular muscle mass. Arch Intern Med 1983; 142:90-92.
5. Devereux RB, Savage DD, Drayer JIM, Laragh JH. Left ventricular hypertrophy and function in high, normal and low renin forms of essential hypertension. Hypertension 1982; 4:524-531.
6. Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Ann Intern Med 1986; 105:649-654.
7. Ferrara LA, Mancini M, De Simone G, Pisanti N, Capone D, Fasano ML. Adrenergic nervous system and left ventricular mass in primary hypertension. Eur Heart J 1989; 10:1036-1040.
8. Bauwens FR, Duprez DA, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1991; 68:925-929.
9. Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J 1998; 135:58-66.
10. Clement DL, De Buyzere M, Duprez D. Prognostic value of ambulatory blood pressure monitoring. J Hypertens 1994; 12:857-864.
11. Morgan HE, Baker KM. Cardiac hypertrophy, Mechanical, neural and endocrine dependence. Circulation 1991; 83:13-25.
12. Sughira N, Shimizu M, Kita Y, Shimizu K, Ino H, Miyamori I, et al. Cardiac characteristics and postoperative courses in Cushing's syndrome. Am J Cardiol 1992; 69:1475-1480.
13. Fallo F, Budano S, Sonino N, Muiesan ML, Agabiti-Rosei E, Boscaro M. Left ventricular structural characteristics in Cushing's syndrome. J Hum Hypertens 1994; 8:509-513.
14. Stewart PM. 11-β-Hydroxysteroid dehydrogenase: implications for clinical medicine. Clin Endocrinol 1996; 44:493-499.
15. Devereux RB, Pini R, Aurigemma GP, Roman MJ. Measurement of left ventricular mass: methodology and expertise. J Hypertens 1997; 15:801-809.
16. Morineau G, Boudi A, Barka A, Gourmelen M, Degeilh F, Hardy N, et al. Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisol-cortisone shuttle. Clin Chem 1997; 43:1397-1407.
17. Hamilton BP, Zadik Z, Edwin CM, Hamilton JH, Kowarski AA. Effect of adrenal suppression with dexamethasone in essential hypertension J Clin Endocrinol Metabol 1979; 48:848-853.
18. Whitworth JA, Gordon D, McLachlan-Troup N, Scoggins BA, Moulds RWF. Dexamethasone suppression in essential hypertension: effects on cortisol and blood pressure. Clin Exp Hypertens (A) 1989; A11:323-335.
19. Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 6:567-574.
20. Sudhir K, Jennings GJ, Esler MD, Korner PI, Blombey PA, Lambert GW, et al. Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function. Hypertension 1989; 13:416-421.
21. Saruto T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome J Clin Endocrin Metabol 1986; 62:275-279.
22. Walker BR, Williams BC. Corticosteroids and vascular tone: mapping the messenger maze. Clin Sci 1992; 82:597-605.
23. van Uum SHM, Hermus ARMM, Smits P, Thien T, Lenders J. The role of 11-β-hydroxysteroid dehydrogenase in the pathogenesis of hypertension (a review). Cardiovascular Res 1998; 38:16-24.
24. Slight SH, Ganjam VK, Gomez-Sanchez CE, Zhou MY, Weber KT. High affinity NAD(1) dependent 11-beta-hydroxysteroid dehydrogenase in the human heart. J Mol Cell Cardiol 1996; 28:781-787.
25. Walker BR, Aggarwal I, Stewart P, Padfield P, Edwards CRN. Endogenous inhibitors of 11 β-hydroxysteroid dehydrogenase in hypertension. J Clin Endocrinol Metabol 1995; 80:529-533.
26. Morris DJ, Lo YH, Lichtfield WA, Williams GH. Impact of dietary Na+ on glyoyrrhetinic acid-like factors (kidney 11-(HSD2)-GALFs) in human essential hypertension. Hypertension 1998; 31:469-472.
27. Mulatero P, Panarelli M, Schiavone D, Rossi A, Mengozai G, Kenyon CJ, et al. Impaired cortisol binding to glucocorticoid receptors in hypertensive patients. Hypertension 1997; 30:1274-1278.
28. Sore A, Ingram MC, Tonolo G, Glorioso N, Fraser R, Evidence of coexisting changes in 11-β-hydroxysteroid dehydrogenase and 5-β-reductase activity in subjects with untreated essential hypertension. Hypertension 1995; 25:67-70.
29. Palermo M, Shackleton CHL, Mantero F, Stewart PM, Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol 1996; 45:605-611.